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Abstract
Objectives: The development of novel agents and an ageing population has led to an 
increasing number of patients with follicular lymphoma (FL) living longer with their dis-
ease. Health- related quality of life (HRQOL) is a priority for patients and should guide 
clinical decisions. The Myeloma Patient Outcome Scale (MyPOS), originally developed 
for myeloma, was validated in a cross- sectional survey recruiting 124 FL patients.
Methods: Content and construct validity, structural validity using confirmatory factor 
analyses, reliability and acceptability were evaluated.
Results: Three subscales were indicated: symptoms and function, emotional response, 
and healthcare support. MyPOS symptom and function scores were higher (worse) in 
participants with poorer ECOG performance status (F=26.2, P<.000) and discriminated 
between patients on and off treatment. Good convergent and discriminant validity in 
comparison to the EORTC- QLQ- C30 and FACT- Lym were demonstrated. Internal con-
sistency was good; α coefficient 0.70- 0.95 for the total MyPOS score and subscales.
Conclusion: The MyPOS is valid, reliable and acceptable, and can be used to support 
clinical care of FL patients. This is the first measurement tool developed specially for 
use in clinical practice that has been validated for use in people with FL. Further longi-
tudinal validation is now required to support its use in outcome measurement.
K E Y W O R D S
factor analysis, Follicular lymphoma, non-Hodgkin lymphoma, psychometrics, quality of life, 
questionnaire validation
1  | INTRODUCTION
In Europe 93 500 new cases of non- Hodgkin’s lymphoma (NHL) were 
diagnosed in 2012, making it the 11th most common cancer. Today 
250 000 people are living with NHL in Europe up to 5 years after being 
diagnosed.1 Follicular lymphoma (FL) is the most common indolent 
form of NHL, accounting for 20% of all NHL in the USA and Western 
Europe.2,3 FL is more common in women, median age at diagnosis 
is 65 years old and incidence increases with age.2 As populations in 
Western Europe and the United States increasingly age, and advances 
in treatment continue to improve survival, healthcare systems face 
growing numbers of people with FL needing long- term care.
FL remains incurable despite considerable improvements in treat-
ment options over the last four decades. The disease trajectory is char-
acterised by patterns of remission and relapse and is without a defined 
optimal management strategy.4 Active monitoring for patients with low 
disease burden is a common strategy but is associated with anxiety as 
patients anticipate inevitable progression of the disease.5 Moreover, 
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any 
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because of the increase in survival, long- term effects of therapy accu-
mulate, among them toxicity- related symptoms, persistent fatigue, de-
pression and anxiety.5-11 These long- term effects have been shown in 
a recent systematic review to impact all dimensions of health- related 
quality of life (HRQOL) even at more than 5 years post- diagnosis.10
Despite these long- term effects, research on HRQOL in NHL and 
FL patients is lacking. Only four studies so far have specifically focused 
on FL patients, documenting the effect of different modes of treat-
ment on return to work and emotional well- being.8,11-13 Two system-
atic reviews of HRQOL in NHL present overall results for this group of 
haematological cancer patients.10,14 Both conclude that the paucity of 
evidence is caused in part by a lack of disease- specific HRQOL mea-
sures. Indeed, prior to 2013 no HRQOL measure was validated for use 
in NHL. The Functional Assessment of Cancer Therapy—Lymphoma 
(FACT- Lym)15 is the only questionnaire available, however, its valida-
tion study does not identify the proportion of FL in the sample. A fur-
ther NHL- specific module of the European Organisation for Research 
and the Treatment of Cancer (EORTC) is currently being developed.16 
Moreover, as HRQOL and other patient- reported outcome measures 
are increasingly used in the clinical care of oncology patients,17-19 a 
different type of measure, suitable for routine clinical use, is needed. 
Measures developed for clinical use differ from HRQOL measures de-
veloped for use in research by a special focus on content and face 
validity, acceptability and interpretability.20
The Myeloma Patient Outcome Scale (MyPOS) is such a measure, 
designed using extensive patient interviews, it is brief and suitable for 
use in clinical practice for measuring myeloma- specific HRQOL.21 Given 
the comparability of disease trajectories (ranging from relatively indo-
lent forms of FL and myeloma- spectrum diseases to relapsed/ refractory 
stages) and treatment- related side effects,11,13,22,23 suitability of MyPOS 
for use in FL is plausible. The objectives of this study are to test the 
construct and structural validity, examine the content validity and ac-
ceptability, and evaluate the reliability of MyPOS in FL patients.
2  | METHODS
2.1 | Setting and population
Between June and August 2013, patients with FL and myeloma were 
recruited for a self- completion, cross- sectional survey from outpatient 
clinics and inpatient wards in 13 hospital trusts in England, including a 
mix of tertiary and district general hospitals (see Acknowledgements 
for list of collaborators). In this paper, we focus on validation results 
for the sample of FL patients. Full details about the methods are 
 reported in the validation study with myeloma patients.24
Patients were included if they were 18 years or older, had a con-
firmed histological diagnosis of FL, were aware of their diagnosis, and 
could give written informed consent. Patients were excluded if they 
were too unwell, symptomatic or distressed to take part (as judged by 
the clinical team), had severe neutropenia, or were unable to under-
stand written or spoken English.
Research Ethics Committee approval was granted by the South 
East London REC- 3 (ref 10/H0808/133) and local approvals were 
obtained from each Research & Development department of all par-
ticipating sites. All participants gave written consent to take part and 
participation was voluntary. Completed questionnaires were screened 
for clinically important issues and where necessary the participant’s 
consent was sought to feed such issues back to the clinical team.
2.2 | Procedure
Consecutive (all available) patients seen on wards or in outpatient clin-
ics at participating sites were screened by clinical teams for eligibil-
ity and if eligible offered the opportunity to participate in the survey 
by research staff. Participants were given the choice to complete the 
questionnaire at the point of recruitment or at a later date and to re-
turn the survey by post. Demographic and clinical data were extracted 
from medical records by research nurses at recruitment.
2.3 | Study measures
Questionnaire booklets contained MyPOS alongside two further 
measures for validation purposes; FACT- LYM and EORTC- QLQ- C30. 
The latter two measures were chosen for testing convergent and di-
vergent construct validity. They represent the only lymphoma- specific 
HRQOL questionnaire and the EORTC’s core cancer questionnaire, 
which has been validated in lymphoma.25
The MyPOS is a 30- item questionnaire, a myeloma- specific version 
of the Palliative Care Outcome Scale (http://pos-pal.org/). The ques-
tionnaire starts with an open question “What are your main problems 
or concerns at the moment?”. This is followed by 27 structured items 
on a 5- point Likert scale. There is one further open question designed 
to pick up problems not covered in the structured items “Please list 
any other symptoms not mentioned above, and tick one box to show how 
they have affected you over the past week”. The MyPOS was developed 
through qualitative investigation of the issues most important to the 
HRQOL of people with myeloma.24 It was initially validated in a sample 
of 380 patients. Factor analysis confirmed three subscales; (i) symp-
toms and function (14 items covering physical symptoms and func-
tional impairments); (ii) emotional response (eight items describing 
the emotional impact of the disease); and (iii) healthcare support (five 
items on information needs and satisfaction with healthcare).24 The 
MyPOS is a valid and reliable tool for use in the routine clinical care of 
myeloma patients.24 For validation, the total MyPOS score (formed by 
summing the scores of the 27 structured items), and subscale scores 
(formed by summing the item scores within each subscale) were used 
for analyses. Higher scores represent worse HRQOL.
The FACT- LYM includes the Functional Assessment of Cancer 
Therapy—General (FACT- G) and fifteen additional disease- specific 
items. Overall it contains 42 questions, each on a 5- point Likert scale, 
and can be combined into five well- being subscales: (i) physical (seven 
items); (ii) social/family (seven items); (iii) emotional (six items); (iv) func-
tional (seven items); and (v) lymphoma- specific additional concerns (15 
items, covering symptoms, patient concerns about symptoms, emo-
tional problems and future care plans). The validity and reliability of 
the FACT- LYM was tested in patients with NHL, with preliminary tests 
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confirming its good internal consistency and a full validation study 
showing its validity and sensitivity to change.26,27 For convergent and 
divergent validity testing, only the individual subscales of the FACT- 
LYM were used. Higher scores represent better functioning.
The EORTC- QLQ- C30 has 30 items on a 4- point scale, combined 
into five subscales (i) physical; (ii) role; (iii) cognitive; (iv) emotional; 
and (v) social functioning. In addition, two 7- point items form a global 
health status scale. All subscale scores were transformed to a 0- 100 
scale following the recommended method.28 High scores on functional 
sub- scales and the global scale represent better functioning, whereas 
high scores on symptom scales represent a worse symptom burden 
and poor HRQOL. Its validation status in NHL is not well supported, 
the only psychometric study having been conducted in a Greek sample 
of 80 NHL patients.25
Clinical characteristics included date of diagnosis, the stage of 
disease at diagnosis,29 current treatment phase ((i) active monitoring/ 
observation; (ii) on active treatment; (iii) on maintenance treatment; 
(iv) progressive/palliative disease), number of lines of treatment 
 (including the current treatment), and Eastern Cooperative Oncology 
Group performance status (ECOG PS).30
2.4 | Statistical analysis
The recruitment target was 111 participants, for detecting differences 
in MyPOS symptom and function subscale scores according to perfor-
mance status, in a one- way ANOVA with small effects (0.03) and 80% 
power. Data was double- entered into an SPSS database. All analyses 
were completed in SPSS v 22.0,31 and in AMOS v. 22.0.32
The following psychometric properties were tested:
1. Construct validity: structural validity (factor analysis). Confirmatory 
factor analysis (CFA) was used to test the retention of the 
three-factor model (symptom and function, emotional response, 
and healthcare support) previously established for MyPOS in 
patients with myeloma.24 The question about sex (item 6 on 
the MyPOS) was excluded from analyses due to a large pro-
portion of missing data. Item parcelling, using the median score 
across four items related to gastro-intestinal symptoms (diarrhoea, 
constipation, nausea and vomiting) was also used to increase 
the participant to item ratio, in line with the recommend 5:1 
ratio.33,34 Factorability of the matrix was tested using Bartlett’s 
test of sphericity, seeking a large significant value indicating the 
MyPOS matrix was significantly different from a matrix with 
no correlations.35 Given our small sample size, factorability was 
further confirmed in SPSS using the Kaiser-Meyer-Olkin Measure 
of Sampling Adequacy (MSA), applying Kaiser’s criteria for ‘good 
factor-analytic’	 of	 MSA≥0.80.36 Initial CFA was carried out on 
the simplest uni-dimensional model, loading all items onto one 
factor. Different three-factor solutions were tested in contrast 
to this model. Three goodness-of-fit indices were used to com-
pare models: Chi-square, Comparative Fit Index (CFI), and the 
Root mean square error of approximation (RMSEA). Because of 
the known limitation of the Chi-square χ2 statistic with its 
sensitivity to sample size, the supplementary index; ratio of χ2 
to degrees of freedom (χ2/df) was used. A ratio of <2 is con-
sidered to reflect good model fit.37 The CFI ranges from 0 to 
1 and compares the model against the null model; a value 
>0.95 is considered representative of good fit.38 For the RMSEA, 
0.08 represents a reasonable fit.39 Factor loadings of items on 
predicted factors were considered acceptable when above 0.30.40 
Communalities (sum of the squared factor loadings) provide an 
estimation of the proportion of total variance explained for each 
item by the final model.
2. Construct validity, known group comparisons. It was hypothesised 
that: (i) MyPOS symptom and function subscale scores would be 
higher (representing worse QoL) in patients with poorer ECOG per-
formance status; and; (ii) that the MyPOS symptom and function 
subscale scores would be higher in patients receiving active treat-
ment compared to those on observation, maintenance or palliative 
treatment. To account for non-normally distributed data, paramet-
ric (ANOVA) and non-parametric (Kruksal Wallis) tests were run in 
parallel. Post hoc, pair-wise T-tests, with Bonferroni adjustment, 
were used to explore differences in means between each group.
3. Construct validity, convergent and divergent validity. A priori hy-
potheses about the nature of correlations between the MyPOS 
total score, MyPOS subscale scores and subscales from the EORTC-
QLQ-C30 and FACT-LYM were specified, using Pearson product-
moment correlation coefficients with missing data excluded 
pairwise. Strong and moderate correlations were predefined as 
>0.70 and >0.50, respectively. It was hypothesised that: (i) MyPOS 
total scores would have a strong to moderate negative correlation 
with the EORTC-QLQ-C30 Global Health Status scale; (ii) MyPOS 
symptoms and function subscale would have a strong to moderate 
negative correlation with the EORTC-QLQ-C30 Physical, Role, 
Cognitive and Social subscales, and the FACT-LYM Physical, 
Functional and Additional Social Well-being subscales; (iii) MyPOS 
emotional response subscale would have a strong to moderate 
negative correlation with the EORTC-QLQ-C30 Emotional sub-
scale, and the FACT-LYM Emotional and Additional Well-Being 
subscales; and (iv) MyPOS healthcare support subscale would not 
correlate strongly with any of the EORTC-QLQ-C30 or FACT-LYM 
subscales as these measures do not contain items on satisfaction.
4. Content validity. Content analysis of the MyPOS open questions 
was used to assess comprehensiveness of the structured items.41 
Responses to the opening question “What are your main problems or 
concerns at the moment?”, and to the second open question “Please 
list any other symptoms not mentioned above, and tick one box to show 
how they have affected you over the past week” were analysed to 
identify symptoms or problems not covered in the MyPOS struc-
tured items.
5. Acceptability and floor/ceiling effects. Acceptability was assessed 
by the proportion of missing data for each MyPOS item. Floor and 
ceiling effects were considered present if more than 15% achieved 
the lowest or highest score.42
6. Internal consistency. Cronbach’s α was determined for MyPOS 
total scores and MyPOS subscales separately. A α coefficient in the 
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range 0.70-0.95 was considered desirable to indicate good internal 
consistency without redundancy of items.41
3  | RESULTS
148 patients with FL were screened by clinical teams, seven were in-
eligible, 12 declined to participate and five withdrew from the study. 
Sample characteristics are shown in Table 1, and reasons for non- 
participation in Fig. S1.
Median age was 66 years old (range: 27- 94). Sixty- two percent of 
respondents were women. Most participants (75.8%) were married or 
partnered, White British (91.1%) ethnic origin, not working or retired 
(75.0%), and not educated beyond college level (79.8%). Forty- four 
percent were managed on active monitoring; 40.3% were receiving 
active or maintenance treatment; and 16.1% were palliative. Sixty- 
eight per cent had ECOG PS 0; 23.4% had ECOG PS 1; 5.6% ECOG 
PS 2; 3.2% ECOG PS 3; and no participant had ECOG PS 4. Median 
time from diagnosis was 34 months (IQ range: 25- 84) at the time of 
questionnaire completion.
3.1 | Structural validity: Confirmatory factor analysis 
(CFA)
Bartlett’s test of sphericity (χ2=1525.0, P<.001) and the MSA (0.848) 
indicated good factorability. Results from the model fit statistics for the 
three models tested with CFA are presented in Table 2. An iterative 
improvement in model fit is indicated with each new model. The final 
model falls short of demonstrating good fit; χ2/df=2.385, CFI=0.774 
and RMSEA=0.109 (90% confidence interval: 0.097- 0.121), despite 
item parcelling increasing the participant to item ratio from 4.5 to 5.1
All items load above 0.30 on the factors predicted (Table 3). 
‘Tingling in hands and/or feet’ was close to the lower threshold, with 
a loading of 0.314, suggesting a weaker correlation between this item 
and other items on the subscale. Eigenvalue estimates report 54.9% of 
the total variance explained by the three factors.
3.2 | Construct validity
The first hypothesis of higher MyPOS symptom and function scores 
in participants with poorer ECOG performance status was confirmed 
(F=26.17, P<.000). The second hypothesis, poorer MyPOS symp-
tom and function scores in those on active treatment versus those 
on maintenance, active monitoring and palliative treatment, was also 
confirmed (F=4.16, P=.008). Figure 1 displays results for the paramet-
ric tests for 120 participants who had complete data for the MyPOS 
symptom and function subscale. Results were confirmed in a sensitiv-
ity analysis using non- parametric tests.
Post- hoc, pair- wise comparisons of the subscale means confirmed 
significant differences between participants on (i) active treatment 
and maintenance treatment (P=.023); and (ii) active treatment and ac-
tive monitoring (P=.010), but non- significant differences between; (iii) 
active treatment and progressive/palliative disease (P=.891).
TABLE  1 Sample characteristics for cross sectional survey 
(n=124)
Age, n, %
<65 55 (44.4)
≥65 69 (55.6)
Median age, range 66 (27- 94)
Gender, n, %
Male 47 (37.9)
Female 77 (62.1)
Marital status, n, %
Single, divorced or separated 16 (12.9)
Married or partnered 94 (75.8)
Widowed 14 (11.3)
Ethnicity, n, %
White British 113 (91.1)
White other 8 (6.5)
Black 2 (1.6)
Other 1 (0.8)
Highest education level, n, %
Primary school 5 (4.0)
Secondary school 54 (43.5)
College/technical qualification 40 (32.3)
University first degree 18 (14.5)
Not known 7 (5.6)
Occupation status, n, %
Working or studying 31 (25.0)
Not working or retired 18 (14.5)
Retired 75 (60.5)
ECOG performance status, n, % (abbreviated descriptions)
0 - Fully active without restriction 84 (67.7)
1 - Restricted in physically strenuous activity but 
ambulatory
29 (23.4)
2 - Ambulatory but unable to do work activities, 
Up>50% of waking hours
7 (5.6)
3 - Limited self- care, confined to bed/chair>50% of 
waking hours
4 (3.2)
4 - Disabled. Cannot carry on any self- care. Totally 
confined to bed/chair
0 (0)
Stage at diagnosis, n, %
I Single lymph node group 17 (13.7)
II Multiple lymph node groups on same side of 
diaphragm
13 (10.5)
III Multiple lymph node groups on both sides of 
diaphragm
33 (26.6)
IV Multiple extranodal sites or lymph nodes and 
extranodal disease
42 (33.9)
Missing 19 (15.3)
Treatment status, n, %
Active treatment 19 (15.3)
Maintenance treatment 31 (25.0)
(Continues)
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3.3 | Convergent and divergent validity
All, apart from one, of the hypotheses were confirmed within the prede-
fined limits (for Pearson correlations see Table S2). MyPOS total scores 
correlated negatively with the EORTC- QLQ- C30 Global Health Status 
scale (r=−.723,	P<.01); MyPOS Symptom & Function scores correlated 
negatively with EORTC- QLQ- C30 Physical function (r=−.791,	P<.01), 
Role function (r=−.838,	P<.01), Cognitive function (r=−.584,	P<.01), and 
Social function (r=−.634,	P<.01). MyPOS Emotional response scores 
correlated negatively with scores on FACT- LYM Emotional well- being 
(r=−.762,	 P<.01), Additional concerns (r=−.729,	 P<.01), and EORTC- 
QLQ- C30 Emotional function (r=−.753,	P<.01). Scores on the MyPOS 
Healthcare support subscale showed no correlation with scores across 
the subscales from FACT- LYM and EORTC- QLQ- C30 QLQ- C30, apart 
from a correlation with the FACT- LYM Additional Concerns scores ex-
ceeding the 0.50 threshold (r=−.518,	P<.01).
3.4 | Content validity
Eighty- eight (80%) participants recorded some free text about their main 
problems or concerns at the beginning of the MyPOS questionnaire. In 
total, 148 main problems or concerns were reported (Tables S4a-S4c), 
with 112 (76%) of these being covered by a subsequent MyPOS item. 
Of the 36 (24%) main problems and concerns not covered by a MyPOS 
item, only weight loss was reported multiple times, three separate 
 participants citing it as a main problem or concern.
After grouping, the largest number of concerns (59 (40%)) were 
about participants worry for their disease or treatment, for example 
“always wondering when the lymphoma will become active again” and 
“worried about having chemo again”, captured by MyPOS items 17, 18, 
21, 22, and to some extent by items 26 and 27.
A total of 44 additional symptoms were recorded after the symp-
tom list on the questionnaire (Table S5). The majority (35) were unique 
symptoms recorded only once. Four were about sweating, two of 
these specifically about night sweats, a further two about problems 
sleeping, and three referred to swelling in the legs, feet or ankles.
3.5 | Acceptability
Ten out of 27 MyPOS items had missing data; most (9) of these were 
missed by just one or two participants (see Table S1). By far the high-
est rate of missing data was observed for the question about sex; 13 
(10.5%) respondents selected ‘rather not say’ on this item. The propor-
tion of missing data overall was low, 0.7% (23 missing responses out 
of a possible 3348). Participants used the full range of responses (0- 4) 
in 19 out of 27 items. For the questions about shortness of breath, 
vomiting, mouth problems, worry about infections, coping with illness, 
and the three items about healthcare support, participants used the 
lower four responses (0- 3) only. Floor effects are evident for all 27 
items; the proportion of answers in the lowest category ranged from 
23.4% to 91.9%. Ceiling effects were not present for any item.
3.6 | Reliability
The MyPOS total and subscale scores showed good internal consist-
ency within the 0.70- 0.95 desired range (Table 3).
4  | DISCUSSION
Together with survival, improved HRQOL is a priority for haematolog-
ical cancer patients.8,13,43,44 Patient- reported monitoring of HRQOL 
Active monitoring 54 (43.5)
Palliative phase 20 (16.1)
Months since diagnosis, n, %
0- 12 29 (23.4)
13- 24 18 (14.5)
25- 36 19 (15.3)
37- 48 6 (4.8)
>48 52 (41.9)
Median months since diagnosis, range 34 (1- 328)
No. of lines of treatment including current, n, %
0 15 (12.1)
1 48 (38.7)
2 37 (29.8)
3 14 (11.3)
More than 3 9 (7.3)
Missing 1 (0.8)
TABLE  1  (Continued)
TABLE  2 Model fit index (n=118)
One factor (no sex; n=118) Three factor (no sex; n=118) Three factor (no sex; gastro parcel; n=118)
No. of items 26 26 23
Chi- square 968.266 710.963 541.477
df 299 296 227
P- value .000 .000 .000
Chi- square/df 3.238 2.402 2.385
Comparative fit index (CFI) 0.567 0.732 0.774
Root mean squared error of 
approximation (RMSEA) [90% CI]
0.138 [0.129- 148] 0.109 [0.099- 0.120] 0.109 [0.097- 0.121]
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facilitates clinician- patient communication about how patients per-
ceive their physical and emotional symptoms, offering the optimal 
avenue to support patients and effect outcomes.18,20 A recent ran-
domised control trial of 766 patients with advanced solid tumours has 
confirmed the clinical benefits associated with patients self- reporting 
of symptoms during cancer care, including; ‘fewer ED visits, fewer 
hospitalisations, longer duration of palliative chemotherapy and supe-
rior quality- adjusted survival’.17
The chronic nature of MM, indolent NHL, and other conditions 
including, chronic lymphocytic leukaemia (CLL) and chronic myeloid 
leukaemia (CML), expose patients to the risk of long- term and accumu-
lated effects of toxicity and adverse psychological effects associated 
with the pattern of disease relapse and remittance.10,23 Routine mon-
itoring of HRQOL may be particularly beneficial in the care of these 
patients, helping to support palliation of symptoms and minimise the 
cumulative negative effects of treatment and disease on HRQOL.14,23 
Of critical importance to greater integration of HRQOL in the clinical 
care of haematological cancer patients is the availability of valid and 
reliable tools, sensitive to specific disease- related outcomes, yet brief, 
and acceptable to patients and clinicians.15
This is the first study to demonstrate the validity and reliabil-
ity of a HRQOL measure for use in patients with FL as a distinct 
patient group. Although the MyPOS was originally developed for 
use in patients with myeloma, similarities between the two diseases 
and a lack of FL- specific tools, led us to validate the MyPOS in FL. 
Fatigue, pain, constipation, peripheral neuropathy, dyspnoea, sleep 
problems, sexual dysfunction, reduced physical and social func-
tioning, and financial problems are common across both patient 
groups.11,13,23 The successful validation of MyPOS in FL supports 
further development and validation of the tool for use in other indo-
lent NHL conditions and chronic haematological malignancies such 
as CLL and CML.
Sensitivity to the individualistic nature of QOL is supported in the 
MyPOS through the inclusion of open text questions. This provides an 
opportunity for clinicians to discover what matters most to patients, 
helping to support patient centred care.20 Analysis of the free text 
recorded by patients established good content validity for MyPOS. 
Patient’s ‘main problems and concerns’ were comprehensively covered. 
Worry about disease or treatment was prominent, reaffirming the im-
portance of comprehensively capturing these issues in the MyPOS.13,23 
Weight- loss, problems sleeping, sweating and lower limb swelling are 
identified as potential areas for extending the symptom list, and should 
be explored in further qualitative interviews with FL patients.
Despite less than good overall model fit for the final model in the 
factor analysis, the individual item factor loadings, and the improve-
ment in model fit from the unidimensional to the final model, suggest 
the three factor model established for MyPOS;24 (i) symptoms and 
function; (ii) emotional response; (iii) healthcare support, holds for use 
in FL patients. Model fit, and lower loading of the item about tinging 
in hands and feet, which has relatively high prevalence in this sample, 
comparable to that of pain, warrant further exploration in a larger sam-
ple. The aligning of items on symptoms and function further supports 
the theoretical model underpinning the development of the MyPOS, 
namely the importance of capturing the indirect effect of physical 
problems on functioning and HRQOL.21,24
MyPOS performs well as a tool for differentiating between patient 
groups. In line with existing evidence, patients with lower perfor-
mance status and those on active treatment had worse symptoms and 
function.11,13 Total MyPOS and MyPOS subscale scores also behaved 
as expected against existing validated measures, the FACT- LYM and 
EORTC- QLQ- C30. Lack of correlation between the MyPOS healthcare 
support subscale further supports recognition of these factors as a 
separate domain within overall HRQOL.
Qualitative evidence supporting the development of MyPOS high-
lighted the importance patients place on issues pertaining to satis-
faction with healthcare staff and information needs.21 Two questions 
in the original FACT- G measures,45 and four in the earlier myeloma- 
specific version of the EORTC; the MY24,46 related to these issues 
have since been removed after observing that most patients respond 
positively. We have similarly observed floor effects for the five items 
on the MyPOS healthcare support subscale, however, given the im-
portance of these issues in routine clinical care, these items are re-
tained in the MyPOS and further strengthen its use as a clinical tool.
The three dimension model is further supported by the demon-
stration of good internal consistency with no suggestion of redun-
dancy of items.41
F IGURE  1 Known group comparisons showing MyPOS symptoms 
and function subscale scores (mean and 95% CI) by treatment status 
and ECOG performance status (n=120)
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4.1 | Methodological limitations
This study is limited by its cross- sectional design. Validity and reli-
ability, including longitudinal and inter- rater reliability have been es-
tablished for the generic Palliative Care Outcome Scale from which 
the MyPOS is derived,47 and work is currently underway to evaluate 
the test- retest reliability and responsiveness of MyPOS in detecting 
clinically important differences in myeloma patients over time.48 This 
longitudinal analysis will strengthen our understanding of how to most 
effectively use MyPOS to improve patient care. Nevertheless, further 
disease- specific longitudinal validation of MyPOS in FL patients is 
needed to support the clinical use of this tool in measuring patient 
outcomes.
We did not seek access to records to compare our sample to the 
demographic and clinical characteristics of the wider group of patients 
registered at participating sites. Consecutive recruitment was used 
to maximise representativeness, and age and gender distributions re-
flected those in the wider FL population in the UK.2 However, per-
formance status and length of illness in our sample suggest that the 
very sickest patients, perhaps because they were non- ambulatory and 
confined to their homes, were excluded from our sampling frame. This 
is reflected in the presence of floor effects in many items. Further in-
vestigation of the acceptability of the MyPOS in a less- well population 
of FL patients would be beneficial. Moreover, given the original pur-
pose of this tool, for use with myeloma patients, further qualitative 
work involving in- depth cognitive interviews with FL patients to eval-
uate comprehensiveness of the MyPOS items in covering main symp-
toms and problems in this population is needed.
The MyPOS has previously been demonstrated to be brief, with 
myeloma patients taking on average (mean) 7 minutes 19 seconds to 
complete the measure. Information on time taken to complete the 
MyPOS was recorded by research nurses for only 6 FL patients in this 
sample and is therefore not reported, this is an omission and should be 
prioritised in future studies.
Finally, we acknowledge that the confirmatory factor analysis was 
limited by a small participant to item ratio. Of main concern is that 
the structural validity of the item concerning worry about sex life has 
not been established, and the overall fit of the model fell short of pre-
defined thresholds for ‘good fit’, therefore further factor analysis with 
a larger sample is required.
TABLE  3 Confirmatory factor analysis (Model 3): standardised estimates for item factor loadings and communalities (n=118)
Symptoms & Function 
subscale
Emotional response 
subscale
Healthcare support 
subscale
Squared multiple  
correlations  
(Communalities)Cronbach’s α .871 .867 .749
Items (abbreviated wording used)
01. Pain .623 .388
02. Fatigue or lack of energy .630 .398
03. Shortness of breath .479 .229
04- 07. Gastro Parcel .510 .260
08. Mouth problems .471 .222
09. Poor mobility .737 .543
10. Tingling in hands or feet .314 .098
11. Difficulty remembering .557 .311
12. Usual activities .846 .717
13. Hobbies and leisure .847 .717
14. Quality time with friends .702 .493
16. Feeling depressed .760 .577
17. Anxious about illness .818 .669
18. Worry about infections .561 .314
19. Worry about appearance .651 .424
20. Worry about finance .534 .285
21. Worry illness get worse .816 .666
22. Able to cope with illness .769 .591
23. Advice if needed .710 .504
24. Good knowledge & skill .890 .792
25. Show care & respect .826 .682
26. Info about illness .564 .318
27. Info about future .457 .208
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5  | CONCLUSION
MyPOS, a measure originally developed for use with myeloma pa-
tients, is a brief, valid, reliable and acceptable tool for assessing the 
HRQOL of patients with FL in a clinical setting. Longitudinal validation 
is now needed to establish test- retest reliability and responsiveness of 
the measure to clinical changes over time, to further support the use 
of the MyPOS in the routine clinical care of FL patients. Furthermore, 
this work supports the case for validating the MyPOS in similar indo-
lent NHL conditions and other chronic haematological malignancies 
including CLL and CML.
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